Cargando…

Evaluation of serum VIP and aCGRP during pulmonary exacerbation in cystic fibrosis: A longitudinal pilot study of patients undergoing antibiotic therapy

BACKGROUND: Objective monitoring of improvement during treatment of pulmonary exacerbation can be difficulty in children when pulmonary function testing cannot be obtained. Thus, the identification of predictive biomarkers to determine the efficacy of drug treatments is of high priority. The major a...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Keilani, Maha S., Awad, Samah, Hammouri, Hanan M., Al Shalakhti, Tala, Almomani, Basima A., Dahabreh, Muna M., Ajlony, Mohammad-Jaafar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162560/
https://www.ncbi.nlm.nih.gov/pubmed/37146001
http://dx.doi.org/10.1371/journal.pone.0284511
_version_ 1785037721159335936
author Al-Keilani, Maha S.
Awad, Samah
Hammouri, Hanan M.
Al Shalakhti, Tala
Almomani, Basima A.
Dahabreh, Muna M.
Ajlony, Mohammad-Jaafar
author_facet Al-Keilani, Maha S.
Awad, Samah
Hammouri, Hanan M.
Al Shalakhti, Tala
Almomani, Basima A.
Dahabreh, Muna M.
Ajlony, Mohammad-Jaafar
author_sort Al-Keilani, Maha S.
collection PubMed
description BACKGROUND: Objective monitoring of improvement during treatment of pulmonary exacerbation can be difficulty in children when pulmonary function testing cannot be obtained. Thus, the identification of predictive biomarkers to determine the efficacy of drug treatments is of high priority. The major aim of the current study was to investigate the serum levels of vasoactive intestinal peptide (VIP) and alpha calcitonin gene related peptide (aCGRP) of cystic fibrosis pediatric patients during pulmonary exacerbation and post-antibiotic therapy, and possible associations of their levels with different clinicopathological parameters. METHODS: 21 patients with cystic fibrosis were recruited at onset of pulmonary exacerbation. Serum was collected at time of admission, three days post-antibiotic therapy, and two weeks post-antibiotic therapy (end of antibiotic therapy). Serum VIP and aCGRP levels were measured using ELISA. RESULTS: Overall least square means of serum aCGRP level but not VIP changed from time of exacerbation to completion of antibiotic therapy (p = 0.005). Serum VIP was significantly associated with the presence of diabetes mellitus (p = 0.026) and other comorbidities (p = 0.013), and with type of antibiotic therapy (p = 0.019). Serum aCGRP level was significantly associated with type of antibiotic therapy (p = 0.012) and positive Staphylococcus aureus microbiology test (p = 0.046). CONCLUSION: This study could only show significant changes in serum aCGRP levels following treatment of pulmonary exacerbations. Future studies with larger sample size are required to investigate the clinical importance of VIP and aCGRP in cystic fibrosis patients.
format Online
Article
Text
id pubmed-10162560
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-101625602023-05-06 Evaluation of serum VIP and aCGRP during pulmonary exacerbation in cystic fibrosis: A longitudinal pilot study of patients undergoing antibiotic therapy Al-Keilani, Maha S. Awad, Samah Hammouri, Hanan M. Al Shalakhti, Tala Almomani, Basima A. Dahabreh, Muna M. Ajlony, Mohammad-Jaafar PLoS One Research Article BACKGROUND: Objective monitoring of improvement during treatment of pulmonary exacerbation can be difficulty in children when pulmonary function testing cannot be obtained. Thus, the identification of predictive biomarkers to determine the efficacy of drug treatments is of high priority. The major aim of the current study was to investigate the serum levels of vasoactive intestinal peptide (VIP) and alpha calcitonin gene related peptide (aCGRP) of cystic fibrosis pediatric patients during pulmonary exacerbation and post-antibiotic therapy, and possible associations of their levels with different clinicopathological parameters. METHODS: 21 patients with cystic fibrosis were recruited at onset of pulmonary exacerbation. Serum was collected at time of admission, three days post-antibiotic therapy, and two weeks post-antibiotic therapy (end of antibiotic therapy). Serum VIP and aCGRP levels were measured using ELISA. RESULTS: Overall least square means of serum aCGRP level but not VIP changed from time of exacerbation to completion of antibiotic therapy (p = 0.005). Serum VIP was significantly associated with the presence of diabetes mellitus (p = 0.026) and other comorbidities (p = 0.013), and with type of antibiotic therapy (p = 0.019). Serum aCGRP level was significantly associated with type of antibiotic therapy (p = 0.012) and positive Staphylococcus aureus microbiology test (p = 0.046). CONCLUSION: This study could only show significant changes in serum aCGRP levels following treatment of pulmonary exacerbations. Future studies with larger sample size are required to investigate the clinical importance of VIP and aCGRP in cystic fibrosis patients. Public Library of Science 2023-05-05 /pmc/articles/PMC10162560/ /pubmed/37146001 http://dx.doi.org/10.1371/journal.pone.0284511 Text en © 2023 Al-Keilani et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Al-Keilani, Maha S.
Awad, Samah
Hammouri, Hanan M.
Al Shalakhti, Tala
Almomani, Basima A.
Dahabreh, Muna M.
Ajlony, Mohammad-Jaafar
Evaluation of serum VIP and aCGRP during pulmonary exacerbation in cystic fibrosis: A longitudinal pilot study of patients undergoing antibiotic therapy
title Evaluation of serum VIP and aCGRP during pulmonary exacerbation in cystic fibrosis: A longitudinal pilot study of patients undergoing antibiotic therapy
title_full Evaluation of serum VIP and aCGRP during pulmonary exacerbation in cystic fibrosis: A longitudinal pilot study of patients undergoing antibiotic therapy
title_fullStr Evaluation of serum VIP and aCGRP during pulmonary exacerbation in cystic fibrosis: A longitudinal pilot study of patients undergoing antibiotic therapy
title_full_unstemmed Evaluation of serum VIP and aCGRP during pulmonary exacerbation in cystic fibrosis: A longitudinal pilot study of patients undergoing antibiotic therapy
title_short Evaluation of serum VIP and aCGRP during pulmonary exacerbation in cystic fibrosis: A longitudinal pilot study of patients undergoing antibiotic therapy
title_sort evaluation of serum vip and acgrp during pulmonary exacerbation in cystic fibrosis: a longitudinal pilot study of patients undergoing antibiotic therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162560/
https://www.ncbi.nlm.nih.gov/pubmed/37146001
http://dx.doi.org/10.1371/journal.pone.0284511
work_keys_str_mv AT alkeilanimahas evaluationofserumvipandacgrpduringpulmonaryexacerbationincysticfibrosisalongitudinalpilotstudyofpatientsundergoingantibiotictherapy
AT awadsamah evaluationofserumvipandacgrpduringpulmonaryexacerbationincysticfibrosisalongitudinalpilotstudyofpatientsundergoingantibiotictherapy
AT hammourihananm evaluationofserumvipandacgrpduringpulmonaryexacerbationincysticfibrosisalongitudinalpilotstudyofpatientsundergoingantibiotictherapy
AT alshalakhtitala evaluationofserumvipandacgrpduringpulmonaryexacerbationincysticfibrosisalongitudinalpilotstudyofpatientsundergoingantibiotictherapy
AT almomanibasimaa evaluationofserumvipandacgrpduringpulmonaryexacerbationincysticfibrosisalongitudinalpilotstudyofpatientsundergoingantibiotictherapy
AT dahabrehmunam evaluationofserumvipandacgrpduringpulmonaryexacerbationincysticfibrosisalongitudinalpilotstudyofpatientsundergoingantibiotictherapy
AT ajlonymohammadjaafar evaluationofserumvipandacgrpduringpulmonaryexacerbationincysticfibrosisalongitudinalpilotstudyofpatientsundergoingantibiotictherapy